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ABSTRACT
The FDA-approved anti-DNA virus agent cidofovir (CDV) is being evaluated in 
phase II/III clinical trials for the treatment of human papillomavirus (HPV)-associated 
tumors. However, previous observations had shown that CDV also inhibits the growth 
of vascular tumors induced by fibroblast growth factor-2 (FGF2)-transformed FGF2-T-
MAE cells. Here, we demonstrate that CDV inhibits metastasis induced by FGF2-driven, 
virus-independent tumor cells. Pre-treatment of luciferase-expressing FGF2-T-MAE 
cells with CDV reduced single cell survival and anchorage-independent growth in 
vitro and lung metastasis formation upon intravenous inoculation into SCID mice. 
This occurred in the absence of any effect on homing of FGF2-T-MAE cells to the 
lungs and on the growth of subconfluent cell cultures or subcutaneous tumors in 
mice. Accordingly, CDV protected against lung metastasis when given systemically 
after tumor cell injection. Lung metastases in CDV-treated mice showed reduced Ki67 
expression and increased nuclear accumulation of p53, indicating that CDV inhibits 
metastasis by affecting single cell survival properties. The anti-metastatic potential of 
CDV was confirmed on B16-F10 melanoma cells, both in zebrafish embryos and mice. 
These findings suggest that CDV may have therapeutic potential as an anti-metastatic 
agent and warrants further study to select those tumor types that are most likely to 
benefit from CDV therapy.
INTRODUCTION
The nucleotide analogue cidofovir [(S)-1-(3-
hydroxy-2-phosphonyl-methoxypropyl)cytosine, CDV] 
is a broad-spectrum antiviral agent approved (Vistide®) 
for the treatment of cytomegalovirus-induced retinitis in 
AIDS patients [1,2].
Besides its antiviral activity, CDV possesses potent 
anti-tumor activity in various experimental models of 
virus-associated tumors [3-8]. In vitro, CDV inhibits the 
proliferation of HPV-positive (HPV+) cervical carcinoma 
cells by accumulation of cells in the S-phase, induction of 
apoptosis and stimulation of the tumor suppressor proteins 
p53 and pRb [8,9]. Moreover, a synergistic effect of CDV 
and radiation was observed in HPV18+ cervical carcinoma 
cells [10] and in head and neck squamous cell carcinoma 
cells [11]. This effect was attributed, at least in part, to 
inhibition of angiogenesis mediated by p53-dependent 
reduction in vascular endothelial growth factor (VEGF) 
expression [10]. 
In keeping with these observations, CDV proved 
active in patients with recurrent Epstein-Barr virus-
induced nasopharyngeal carcinoma (NPC) and is 
increasingly being used off-label to treat a variety of 
human papillomavirus (HPV)-induced premalignant and 
malignant lesions [12-15]. In fact, intralesional CVD has 
been one of the mainstays of adjuvant therapy in patients 
with recurrent respiratory papillomatosis (RRP) since 
1998 [16]. Moreover, CDV has recently been evaluated 
in phase II clinical trials for HPV-associated high grade 
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cervical and vulvar carcinoma and showed promise for 
topical treatment of cervical intraepithelial neoplasia grade 
(CIN) 2+ lesions [17]. 
Besides its virus-related antineoplastic activity, 
increasing evidence indicates that CDV may show 
therapeutic efficacy in cancer beyond the setting of viral 
infection. Indeed, CDV inhibits intracranial glioblastoma 
growth by promoting DNA double-strand breaks and 
apoptosis following its incorporation into the DNA [18]. 
Also, CDV proved effective in the treatment of patients 
with basal cell carcinoma [19] and cutaneous squamous 
cell carcinoma [20].
Fibroblast growth factor-2 (FGF2) was one of the 
first angiogenic factors to be described [21]. Over the 
years the FGF2/FGF receptor (FGFR) system has been 
shown to play a major role in angiogenesis, inflammation 
and in the development and progression of angiogenic 
diseases and cancer [22-24]. Moreover, accumulating 
evidence indicates that FGF2 is involved in resistance of 
tumor vascularization against VEGF inhibitor treatment. 
Therefore, FGF2 and FGFRs have gained interest as 
promising targets for drug development in cancer therapy 
[25,26]. In this setting, we generated a stable oncogenic 
FGF2-overexpressing endothelial (FGF2-T-MAE) 
cell line able to induce highly vascularized tumors that 
histologically resemble Kaposi’s sarcoma when grafted 
in immunocompromised mice [4,27,28]. Thus, FGF2-T-
MAE cells represent an interesting model of FGF2-driven 
tumor development and for assessing the efficacy of anti-
FGF2 therapeutic approaches. Notably, CDV inhibits the 
growth of primary tumors induced by FGF2-T-MAE cells 
that do not express viral oncogenes. The cytostatic and 
pro-apoptotic activity of CDV in these cells was found to 
be mediated by increased p53 protein levels and inhibition 
of FGF2 expression [29]. Relevant to this point, CDV also 
inhibits the in vivo growth of murine B16 melanoma cells 
[30], a FGF2-dependent tumor cell line [26 and references 
therein]. Accordingly, intralesional injection of CDV 
has been shown to cause the regression of a cutaneous 
metastasis in a melanoma patient [31].
Metastasis remains the primary cause of mortality 
in cancer patients. This is mainly due to the fact that 
micrometastases largely remain unidentified. Thus, the 
identification and characterization of compounds able 
to prevent the development of micrometastases and/
or metastatic colonization, remains a challenge [32,33]. 
Previous observations had shown that CDV exerts an anti-
metastatic activity in one experimental model involving 
HPV+ cells [34]. In the present study, we show that CDV 
inhibits the metastatic growth of virus-independent, 
FGF2-driven FGF2-T-MAE and melanoma B16 tumors. 
Evidence is provided that this is associated with the 
inhibition of single cell survival properties of tumor cells. 
RESULTS
CDV reduces single cell survival of F2T-luc2.9 
cells
We previously showed that the cytostatic activity 
of CDV in FGF2-T-MAE cells increases with decreasing 
seeding density [29]. Therefore, we assessed whether 
CDV affects the capacity of luciferase-expressing FGF2-
T-MAE cells (F2T-luc2.9 cells) to survive as single cells. 
We first examined toxicity in subconfluent F2T-
luc2.9 cell cultures. Cells were incubated with various 
concentrations of CDV for 24 h, washed and grown in 
fresh medium without compound for 5 days. Cell viability 
was determined at different time points. As previously 
shown for HPV+ cells (and due to the long half-life of 
CDV), cytotoxicity of CDV increased with time, in 
particular from 1 to 3 days after CDV treatment (Fig. 1A), 
resulting in CC50 values (concentration that reduces the 
number of living cells by 50%) that decreased from >100 
µg/ml 24 h after CDV treatment to 71, 49 and 45 µg/ml 
after 2, 3 and 6 days, respectively (Fig. 1B). 
Next, F2T-luc2.9 cells, pretreated for 24 h with 
different concentrations of CDV, were seeded as single 
cells in the absence of CDV. Colony formation was 
evaluated after 7 days. CDV significantly inhibited single 
cell survival and growth (Fig. 1C) at concentrations that 
did not inhibit subconfluent cultures, as reflected by the 
reduced number of colonies and smaller colony size 
(Fig. 1D) of cells pretreated with 10 or 20 µg/ml CDV. 
At 50 µg/ml, no colonies could be detected, whereas this 
concentration still allowed 50% survival in subconfluent 
cultures (Fig. 1A). Additionally, we determined the effect 
of CDV on detachment-free survival of F2T-luc2.9 cells 
seeded on agarose. Again, CDV pretreatment (at 10 and 
20 µg/ml) dose-dependently inhibited the clonogenic 
capacity of the cells (Fig. 1C). These data suggest that 
CDV may affect the survival of single cells in the blood 
(in suspension) or after extravasation in the target organ. 
CDV pretreatment inhibits lung metastasis of 
F2T-luc2.9 cells without affecting primary tumor 
growth
Prompted by these results we investigated whether 
CDV inhibits the metastatic potential of F2T-luc2.9 
cells after intravenous injection in SCID mice. This 
experimental metastasis model recapitulates all post-
intravasation steps of tumor cell metastasis [35]. 
F2T luc2.9 cells were retained in the lungs within 
1h after inoculation into the tail vein (Fig. 2A). The 
luminescent signal, reflecting the amount of living tumor 
cells in the lungs, progressively declined during the next 
days, leaving a small number of viable cells that remained 
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dormant for approximately 3 weeks. Next, disease 
progression occurred, as indicated by the exponential 
increase in luminescent signal in the lungs. 
In order to evaluate the anti-metastatic properties 
of CDV, F2T-luc2.9 cells were pretreated with 10 µg/
ml of CDV for 24 h, i.e. the lowest concentration that 
inhibited single cell survival in vitro (Fig. 1C). Consistent 
with the in vitro data, CDV pretreatment resulted in a 
significant reduction in tumor cell survival in the lungs 
compared with control cells. Indeed, the luminescent 
signal decreased 8-fold from day 0 to day 5 after injection 
for control cells versus 16-fold for CDV-treated cells 
(Fig. 2A). Moreover, outgrowth of the surviving cells into 
macrometastases proceeded more slowly for CDV-treated 
cells, the luminescent signal increasing more than 100-
fold from day 19 to 36 for control cells versus 13-fold for 
CDV-treated cells. This resulted in a significantly reduced 
weight of harvested lungs at the end of the experiment 
(Fig. 2C). 
CDV was previously shown to inhibit the homing 
of HPV+ cells to the lungs by inhibition of CXCR4 
expression and signaling [34]. However, one hour after 
cell inoculation equal numbers of luciferase-expressing 
tumor cells were observed in the lungs of control and 
Figure 1: CDV inhibits single cell survival and anchorage-independent growth of F2T-luc2.9 cells. F2T-luc2.9 cells were 
seeded at 10,000 cells/cm2. After overnight incubation, the cells were treated with different concentrations of CDV for 24 h. A, B, Cells 
were washed and incubated in fresh medium without CDV. Cell survival was measured at multiple time points by MTS assay (A) and 
CC50 values (concentration that reduces cell number by 50%) were determined (B). C, D, For single cell survival 300 pretreated cells were 
seeded in 6-well plates in the absence of CDV. After 7 days, the number of colonies (C) and the cells in each colony (D) were determined. 
*p<0.05; Student-t-test. For anchorage-independent growth 50,000 pretreated cells were seeded on soft agar in the absence of CDV. After 
14 days, the colonies were counted (C). #p<0.05; Student-t-test. Representative pictures of cell colonies on culture dish (upper panel) and 
agar (bottom panel) are shown. Values are expressed as mean ± S.E.M. of 3 independent experiments in duplicate.
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Figure 2: CDV pretreatment of F2T-luc2.9 cells inhibits metastasis but not primary tumor growth. F2T-luc2.9 cells were 
grown for 24 h in the absence or presence of 10 µg/ml of CDV. Next, SCID mice were injected i.v. (A-D) or subcutaneously (E-G) with 
106 control or CDV-treated cells. At regular time intervals, the mice were imaged to assess the growth of luciferase-positive metastases 
(A) or subcutaneous primary tumors (E). At the end of the experiment, the lungs (C) or subcutaneous tumors (G) were dissected and 
weighed. Representative pictures of bioluminescence are shown (B, F). Dotted line in C indicates normal lung weight. Three independent 
experiments yielded comparable data. Values are expressed as mean ± S.E.M. of one experiment, n = 5. D, One million cells/200 µl were 
injected in the tail vein of SCID mice. At indicated time points, lungs were perfused and single-cell suspensions generated. 5 x 104 lung-
derived cells were plated into a 10-cm tissue culture dish and cultured in F2T-luc2.9-specific medium. Colonies were counted after 14 days. 
*p < 0.05; Student-t-test.
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CDV-treated groups (Fig. 2A). Also, CDV did not affect 
F2T-luc2.9 cell adhesion to the extracellular matrix (ECM) 
components collagen I, laminin, or fibronectin or to an 
endothelial cell layer (data not shown). Together, these 
data indicate that CDV does not influence initial retention/
homing of F2T-luc2.9 cells in the lungs.
Figure 3: Systemic CDV treatment inhibits the development and growth of F2T-luc2.9 lung metastases. A-F, 106 cells/200 
µl were injected i.v. in SCID mice. CDV was administered i.p. at 150 mg/kg, once weekly from 2 h after cell inoculation till the end of the 
experiment. At regular time intervals, the mice were imaged to assess the growth of luciferase-positive metastases (A). At the end of the 
experiment, the lungs were dissected and weighed (C). Representative pictures of bioluminescence in the lungs of control and CDV-treated 
mice (B), macroscopic pictures (D) and H&E staining (F) of lungs from control and CDV-treated mice after 39 days are shown. Arrowhead 
indicates micrometastasis. Two independent experiments yielded comparable data. Results of one experiment are shown. Values are 
expressed as mean ± S.E.M. (n = 5), *p < 0.05, Student-t-test. E, Western blot analysis for FGF2 on homogenized and lysed lungs from 
control and CDV-treated mice and from normal healthy mice (NC, negative control). 
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To further investigate the growth potential of lung-
arrested tumor cells, lungs were harvested at different time 
points after cell injection. Then, single cell suspensions 
were generated and allowed to grow for 2 weeks in 
hygromycin-containing medium selective for F2T-luc2.9 
cells (Fig. 2D). As anticipated, no difference was observed 
in the number of colonies obtained from lungs containing 
control or CDV-pretreated cells shortly after injection 
(30 min). However, the colony-forming capacity of 
CDV-pretreated cells appeared to be reduced when lungs 
were harvested 24 h after cell injection; this effect was 
statistically significant for cells isolated 7 days after cell 
injection. 
On this basis, to assess whether CDV pretreatment 
affects the intrinsic growth potential of F2T-luc2.9 cells, 
CDV-pretreated cells (10 µg/ml, 24 h) were injected 
subcutaneously in SCID mice. At variance with the 
inhibitory effect exerted by CDV pretreatment on the 
development of F2T-luc2.9 lung metastases, no significant 
difference in subcutaneous tumor growth could be 
observed between control and CDV-treated cells (Fig. 2E, 
F). Accordingly, the weight of the primary subcutaneous 
tumors harvested 3 weeks after cell injection was not 
different in the two groups (Fig. 2G). Thus, pretreatment 
with a low dose of CDV does not affect the intrinsic 
growth of subcutaneous tumor grafts generated by F2T-
luc2.9 cells but hampers single cell survival in vitro and 
metastatic growth in vivo. 
Systemic treatment with CDV impairs lung 
metastasis of F2T-luc2.9 cells
Next, we examined whether CDV also protects 
against lung metastasis when given systemically after 
tumor cell injection, i.e. in a therapeutic treatment setting. 
The anti-metastatic activity of CDV was evaluated at 150 
mg/kg i.p., once weekly, a concentration that suppresses 
FGF2-T-MAE primary tumor growth without eliciting 
systemic toxicity [4]. When treatment was started 1 h 
after cell inoculation and sustained for 6 weeks, CDV 
significantly reduced tumor cell survival and outgrowth 
in the lungs (Fig. 3A), resulting in a markedly reduced 
metastatic burden and lung weight (470 ± 220 mg 
versus 170 ± 23 mg for control and CVD-treated mice, 
respectively) (Fig. 3A-C). Macroscopically, lung tumors 
were detected in all control animals whereas 83% of 
CDV-treated mice appeared tumor-free (Fig. 3D). Also, 
Western blot analysis performed on lung homogenates 
from control and 3F2T.luc2-injected animals harvested 
5 weeks after cell injection showed a high expression of 
FGF2 isoforms, an index of the presence of F2T-luc2.9 
cell-derived metastases in control lungs. In contrast, low 
levels of FGF2 were detectable in the lungs from CDV-
treated animals (Fig. 3E). Histological analysis confirmed 
these observations (Fig. 3F) and showed the presence of 
microscopically detectable lesions in the lungs of CDV-
treated mice, indicating that the development of lung 
metastases was delayed, but not completely prevented, by 
systemic CDV treatment. 
In a second set of experiments, mice were inoculated 
with a high amount of cells to assess the effect of systemic 
CDV treatment on animal survival. As shown in Fig. 4A, 
control mice died 31 ± 2 days after tumor cell inoculation. 
In contrast, 60% or 29% of the animals were still alive at 
day 57 when CDV treatment was initiated 1 h or 2 days 
after cell inoculation and continued till the end of the 
experiment. At this time point, surviving animals showed 
signs of progressing illness and were euthanized. Thus, 
CDV protects against lung metastasis when treatment 
is delayed till 2 days post tumor cell injection, but the 
inhibitory effect was less pronounced compared with the 
early treatment group (Fig. 4), suggesting that CDV may 
act at different steps of the metastatic process after tumor 
cell homing. 
Figure 4: Effect of delayed CDV treatment on 
metastasis-induced mortality. A, B, 2 x 106 F2T-luc2.9 cells 
were injected into the tail vein of SCID mice. CDV treatment 
(150 mg/kg i.p., once weekly) was started either 2 h or 2 days 
after cell inoculation and continued for 5 weeks, when the lungs 
were dissected and weighed (B). Mortality was determined in 
a parallel group of animals (A). Two independent experiments 
yielded comparable data. Results of one experiment are shown. 
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CDV increases nuclear accumulation of p53
CDV has been shown to reduce FGF2-T-MAE 
tumor growth by inducing apoptosis via the upregulation 
of p53 [4,29]. Thus we reasoned that similar mechanisms 
might be responsible for the anti-metastatic activity of the 
drug. 
Immunohistochemistry (Fig. 5) was performed on 
lung metastases from mice that were i.v. injected with 
untreated F2T-luc2.9 cells (control), CDV-pretreated cells 
or naïve cells followed by systemic CDV treatment. Five 
weeks after cell injection, metastases of various sizes 
were detected throughout control lungs (Fig. 5A). Large 
(> 1 mm) and medium-size (200 µm-1 mm) metastases 
showed high expression of the proliferation marker Ki67, 
both in the center and at the tumor rim, and were highly 
vascularized, whereas micrometastases (<200 µm) stained 
Figure 5: Immunohistochemical analysis of F2T-luc2.9 cell-induced lung metastases. Immunohistochemical analysis was 
performed on lung metastases from mice collected 5 weeks after i.v. injection of either untreated F2T-luc2.9 cells (control), untreated cells 
with systemic CDV treatment (150 mg/kg.week) or CDV-pretreated (10 µg/ml, 24 h) cells. A, Total lung sections were stained with H&E. 
Large- (>1 mm), medium- (200 µm-1 mm) and small-size (<200 µm) metastases were counted. Scale bars: 1 mm. Values are expressed as 
mean ± S.E.M. (n = 5), *p < 0.05, Student-t-test. B, Control metastases are highly proliferative as indicated by prominent Ki67 staining. 
C, Metastases of comparable size (indicated by the arrows in A) were double immunostained with anti-CD31 (red) and anti-Ki67 (green) 
antibodies, followed by nuclear counterstaining with DAPI (blue). Scale bars: 50 µm. D, Ki67 (green)-negative tumors are detected in CDV 
groups, but not in control lungs, and are characterized by predominant nuclear p53 staining (red). Scale bars: 50 µm.
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positive for Ki67 (Fig. 5B, C) but appeared to contain 
fewer blood vessels or were located perivascularly. The 
tumor suppressor protein p53 was expressed either in the 
cytoplasm only (Fig. 5D) or in the cytoplasm and nucleus.
In the group of animals injected with CDV-pretreated 
cells, few vascularized metastases (1-3 per lung section) 
were evident. Even though most metastases expressed 
Ki67, Ki67-negative metastases were characterized by p53 
nuclear localization (Fig. 5D). Similarly, metastases in the 
lungs of CDV-treated mice grafted with naïve F2T-luc2.9 
cells were low in number (1-3 per lung section) and small-
to medium sized (Fig. 5A). Also in this group, medium-
sized lesions did not appear different from control lesions. 
However, at variance with the other experimental groups, 
the lungs of CDV-treated mice were characterized by the 
presence of avascular micrometastases as well as of small 
lesions that did not express Ki67 (Fig. 5C). Again, p53 
was predominantly located in the nucleus of tumor cells in 
all Ki67-negative lesions in this group (Fig. 5D). 
Thus, in keeping with our previous in vitro 
observations on FGF2-T-MAE cells [29], CDV may affect 
the number of F2T-luc2.9 metastases and their growth in 
vivo by reducing Ki67 expression and increasing nuclear 
accumulation of p53.
Figure 6: CDV inhibits the metastatic activity of B16-F10 melanoma cells in zebrafish. DsRed-B16-F10 cells were injected 
in the duct of Cuvier of zebrafish embryos at 48 hpf (80-100 cells/embryo). After 24 h, embryos were transferred to fish water in the absence 
or in the presence of 100 µg/ml of CDV. Micrometastases were observed under a fluorescence stereo microscope and quantified 5 days after 
cell injection by computerized image analysis of the embryo tails. A) Schematic drawing of zebrafish embryo at 7 days post-fertilization (a): 
boxed area highlights the tail region photographed at the end of experimentation. Representative micrometastases (red) in control (b,d) and 
CDV-treated (c,e) animals. B) DsRed-B16-F10 micrometastases were quantified in the whole tail region of each embryo by computerized 
image analysis. Data are the mean ± S.E.M. of 17-20 embryos per group. *p < 0.05; Student-t-test.
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CDV inhibits lung metastasis of B16-F10 
melanoma cells in zebrafish and mice
FGF2-dependent B16-F10 melanoma cells represent 
a prototypic model of experimental metastasis following 
their injection in the bloodstream of mice [36,37] or 
zebrafish embryos [38]. On this basis, given the prominent 
role of FGF2 in tumor progression and metastatic activity 
of these cells [26 and references therein], we investigated 
whether the anti-metastatic potential of CDV could be 
extended also to these virus-independent tumor cells.
Figure 7: CDV pretreatment inhibits lung metastasis of B16-F10-luc2 melanoma cells. B16-F10-luc2 cells were grown 
for 24 h in the absence or presence of 10 or 50 µg/ml of CDV. Next, SCID mice were injected i.v. (A-C) or subcutaneously (D-G) with 
30,000 untreated (control) or CDV-treated cells. At regular time intervals, the mice were imaged to assess the growth of luciferase-positive 
metastases (A, B) or subcutaneous primary tumors (D, E). At the end of the experiment, the lungs (C) or subcutaneous tumors (F, G) were 
dissected. The number of macrocolonies in the lungs was determined (C) and subcutaneous tumors were weighed (G). Representative 
pictures of bioluminescence are shown (B, E). Data are expressed as mean ± S.E.M of 2 independent experiments, n = 10. *p < 0.05; 
Student-t-test.
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In a first set of experiments, DsRed-B16-F10 
melanoma cells were injected into the blood circulation 
of zebrafish embryos at 48 hpf. After 24 h, embryos were 
transferred in fish water in the absence or in the presence 
of 100 µg/ml of CDV and the growth of micrometastases 
in the tail vascular plexus was followed. As shown in Fig. 
6, CDV treatment results in a significant reduction of the 
size of DsRed-labelled micrometastases when assessed 
5 days after cell injection. Of note, CDV did not exert 
any evident toxic effect on the development of zebrafish 
embryos when compared to vehicle-treated animals (data 
not shown).
Next, the effect of CDV on the metastatic activity 
of B16-F10 melanoma cells was assessed in mice. In 
accordance with the data obtained with F2T.luc2.9 cells, 
pretreatment of B16-F10-luc2 cells with CDV abrogated 
lung metastasis after i.v. injection (Fig. 7A-C) without 
affecting primary subcutaneous tumor growth (Fig. 7D-G).
DISCUSSION
Experience with the off-label use of the nucleotide 
analogue CDV and recent clinical trials indicate that CDV 
holds great promise as anti-cancer agent for the treatment 
of high-grade HPV+ carcinomas [16,17]. While CDV 
preferentially acts on E6/E7 viral oncogene-expressing 
cells [9], a recent study showed that the compound also 
inhibits primary glioma growth in human cytomegalovirus 
(HCMV)-infected as well as in non-infected patients [18], 
indicating that this compound may exert anti-tumor effects 
also in virus-independent neoplasms. Indeed, CDV proved 
effective in the treatment of patients affected by basal cell 
carcinoma or cutaneous squamous cell carcinoma [19,20]. 
Moreover, CDV reduces the growth of primary murine 
B16 melanoma tumor grafts [30] and of Kaposi’s sarcoma-
like tumors induced by murine FGF2-overexpressing 
FGF2-T-MAE cells [4,27,28].
Thus far, the anti-metastatic activity of CDV had 
been demonstrated only in one experimental model 
involving HPV+ cells [34]. Here, we provide novel 
evidence that CDV inhibits experimental lung metastases 
induced by virus-independent FGF2-T-MAE-derived 
3F2T.luc2 tumor cells and B16-F10 melanoma cells, the 
growth of both cell lines relying on an autocrine activation 
by FGF2 [4,26]. 
FGF2 activates FGF receptors (FGFRs) 
on endothelial cells, resulting in increased tumor 
vascularization and dissemination of metastatic cells [22]. 
Accordingly, FGF2 has been shown to play an important 
role in the pathology of tumors of endothelial cell origin, 
such as hemangiomas and Kaposi’s sarcoma [39-41]. 
Moreover, levels of circulating FGF2 were suggested to 
have prognostic value in hematological malignancies, 
lung cancer, head and neck cancer and melanoma [22,42-
46]. In other tumor types, such as gastric and esophageal 
cancer and pediatric glioma, intratumoral levels of FGF2 
were shown to correlate with poor clinical outcome [47-
49]. In melanoma, FGF2 upregulation was found to be 
accompanied by the expression of FGFRs that triggers 
an autocrine loop of activation required for melanoma 
growth and survival [22,26,50,51]. Here we show that 
the injection of DsRed-B16-F10 melanoma cells into 
the blood circulation of zebrafish embryos results in 
the growth of micrometastases within 5 days after cell 
injection. Addition of 100 µg/ml of CDV to the fish 
water resulted in a significant reduction in the growth of 
micrometastases, without any evident toxic effect on the 
development of the embryos. Also, pretreatment of B16-
F10-luc2 cells with CDV abrogated single cell survival 
in vitro (data not shown) and lung metastasis after i.v. 
injection in mice, without affecting primary subcutaneous 
tumor growth. The anti-metastatic activity of CDV was 
not limited to B16 melanoma cells. Indeed, our data 
demonstrate the capacity of the compound to affect 
also single cell survival of FGF2-dependent 3F2T.luc2 
tumor cells and their capacity to induce lung metastases 
following i.v. injection in immunocompromised animals. 
These observations pave the way for further studies 
about the anti-cancer activity of CDV in different FGF2-
dependent tumors.
Metastasis is a complex multistep process that 
involves (i) the detachment of tumor cells from the 
primary tumor, (ii) trans-endothelial cell migration, (iii) 
transport of the tumor cells through the blood, (iv) tumor 
cell arrest in a target organ, (v) extravasation into the tissue 
and (vi) outgrowth of the secondary tumor [reviewed in 
32,33]. Thus, compounds that interfere with tumor cell 
invasion, detachment-free survival, angiogenesis and 
resistance to apoptosis may inhibit metastasis. In vitro 
experiments indicate that CDV does not affect F2T-
luc2.9 cell migration or adhesion to the ECM components 
collagen I, laminin, or fibronectin or to an endothelial cell 
layer (data not shown). Amine [34] demonstrated that 
pretreatment of HPV16+ cells with CDV reduces tumor 
cell metastasis by inhibition of E6 and E7 viral oncogene 
expression, leading to decreased CXCR4 levels and 
reduced homing of the cells to the lungs after i.v. injection. 
However, we found that CXCR4 protein expression at the 
cell surface was nearly undetectable both in control and 
CDV-treated F2T-luc2.9 cells, ruling out the possibility 
that the anti-metastatic action exerted by CDV on these 
cells may depend on CXCR4 activity. Accordingly, our 
in vivo observations clearly indicate that CDV does not 
interfere with F2T-luc2.9 cell homing to the lungs.
CDV reduces the in vitro survival of single F2T-
luc2.9 cells both when attached to the substratum or in 
suspension. This occurred at compound concentrations 
that did not affect the survival of subconfluent cell 
cultures. Moreover, pretreatment of F2T-luc2.9 cells with 
CDV reduced lung metastasis after i.v. injection but did 
not affect the growth of a subcutaneous primary tumor, 
pointing to a specific effect of CDV at the single cell level. 
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It is well established that the majority of tumor cells die 
during the first days after arrest in the target organ [52,53]. 
We found that the massive tumor cell death that occurs in 
the lungs from day 0 till day 7 after i.v. injection was even 
more pronounced when F2T-luc2.9 cells were pretreated 
with CDV and correlated with the reduced colony-forming 
capacity of these cells when recovered from the lungs 
7 days after injection. Together, these data suggest that 
CDV may affect the survival of single tumor cell colonies 
or micrometastases in the lung microenvironment [54]. 
However, despite the pro-apoptotic properties of CDV 
[4,5,29], we failed to detect apoptotic tumor cells in the 
lungs of F2T-luc2.9 cell-injected animals 3 and 7 days 
after grafting (data not shown). This could be due to the 
paucity of tumor cells present in the lungs at these time 
points or the fact that apoptotic cells had already been 
phagocytized and cleared.
The progression from a small avascular nodule to 
an aggressively growing secondary tumor requires the 
formation of an intratumoral network of blood vessels 
[32,55]. CDV caused >90% reduction in the number of 
F2T-luc2.9 cell-derived lung metastases with complete 
inhibition of large-size metastases, suggesting that the 
compound inhibits both the survival of micrometastases 
as well as macrometastasis outgrowth. Moreover, whereas 
control metastases were all well vascularized, avascular 
micrometastases were detectable in the lungs of CDV-
treated mice. Accordingly, CDV was shown to reduce the 
expression of pro-angiogenic FGF2 in F2T-luc2.9 cells in 
vitro [29]. In addition, weekly CDV treatment, that results 
in a nearly continuous exposure to the drug due to its long 
half-life [56], was able to maintain micrometastases in a 
dormant state, as shown by the absence of Ki67 expression 
in (some of) these lesions. Notably, all Ki67-negative 
lesions showed predominant nuclear staining of p53, 
whereas p53 was localized solely in the cytoplasm or in 
the cytoplasm and nucleus in Ki67-positive metastases. 
Increased nuclear p53 is likely to result in cell cycle 
arrest [57], as indicated by the absence of Ki67 staining in 
these lesions. These data suggest that the anti-tumor/anti-
metastatic activity of CDV might be limited to tumors in 
which downstream p53 signaling is unaffected.
The p53 pathway has been identified as one of the 
main targets for CDV also in HPV+ tumors in which 
increased p53 levels are linked to reduced expression 
of the viral oncogene E6 [9,10]. Further studies will be 
required to identify the molecular mechanisms linking 
CDV treatment to increased p53 activity in virus-
independent tumors.
Tumor metastases remain the main cause of death 
in cancer patients, mainly due to late diagnosis and the 
lack of efficient anti-metastatic drugs. The present study 
shows for the first time that the FDA-approved antiviral 
agent CDV inhibits lung metastasis of virus-independent 
FGF2-driven tumor cells. The concept of using existing 
drugs for novel applications is very attractive given 
that treatment can be developed fast and with relatively 
low costs [58-61]. Developing a new drug can take 10 
years or more and costs in excess of 1 billion dollars. 
Moreover, despite increasing efforts and money being 
put into research, the number of new drugs approved 
remains constant. Repurposing old compounds has proven 
successful in the past and is gaining in popularity [62-65]. 
In particular, AZT (azidothymidine), a failed anticancer 
drug, was the first antiviral approved for HIV/AIDS in 
1987 [66]. Conversely, the nucleoside analogue Gemzar® 
(gemcitabine) originally developed as an antiviral agent 
is now being used to treat pancreatic cancer [67]. Our 
findings suggest that CDV may have therapeutic potential 
as an anti-metastatic agent and warrant further studies to 
select those tumor types that are most likely to benefit 
from CDV therapy.
MATERIALS AND METHODS
Cidofovir [(CDV, Vistide®] was obtained from 
Gilead Sciences (Foster City, CA)
Cell cultures
FGF2-T-MAE cells are murine endothelial cells that 
express high levels of the Mr 18,000, Mr 22,000 and Mr 
24,000 molecular weight isoforms of FGF2 [27]. These 
cells were maintained in Dulbecco’s modified minimum 
essential medium (DMEM, Life Technologies, Inc., 
Rockville, MD) supplemented with 10 mM Hepes (Life 
Technologies), 10% fetal bovine serum (FBS) , 1 mM 
sodium pyruvate (Life Technologies) and 500 µg/ml 
geneticin (Invitrogen). F2T-luc2.9 cells were engineered 
by selecting the brightest clone of FGF2-T-MAE cells 
transfected with enhanced firefly luciferase (Fluc, 
Promega, Leiden, The Netherlands) under hygromycin 
growth conditions (Invitrogen), as described [68]. B16-
F10-luc2 murine melanoma cells expressing Fluc (Perkin 
Elmer, Zaventem, Belgium) were maintained in DMEM, 
supplemented with 10% FBS. 
Cytotoxicity
Cytotoxicity of CDV was evaluated by the MTS 
method. Briefly, cells were seeded in 96-well plates 
at 10,000 cells per cm2. After overnight incubation at 
37°C, CDV (10, 20, 50 or 100 µg/ml) was added for 24 
h. Next, the cells were washed and incubated with fresh 
medium containing 10% FBS for another 24, 48 or 120 
h. To determine the 50% cytotoxic concentration (CC50), 
the medium was removed and 90 μl medium plus 10 μl 
MTS/PMS (Promega) were added to each well. After 
an incubation period of 2 h at 37 °C, the optical density 
of each well was determined at 498 nm in a microplate 
reader. 
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Anchorage-independent growth
F2T-luc2.9 cells were grown in culture flasks and 
pretreated with different concentrations of CDV (50, 20 
or 10 µg/ml) for 24 h. Next, the cells were trypsinized and 
counted. 5.104 cells were suspended in 2 ml of medium 
containing 0.3% agar and applied onto 2 ml presolidified 
0.6% agar in 6-well plates in the absence of CDV. Medium 
was replaced twice weekly. After 2 weeks of incubation, 
cell colonies were stained with 0.1% crystal violet in 
methanol and counted.
Single cell survival
F2T-luc2.9 cells were treated and seeded as 
described above. Next, 300 cells were seeded in 6-well 
plates in the absence of CDV. After 7 days cell colonies 
were stained and counted.
Animals
Female severe combined immunodeficient (SCID) 
mice, weighing about 20 g were used for all experiments. 
The animals were bred at the animal facility of the Rega 
Institute. All studies were done in compliance with the 
ethical guidelines for animal welfare of the KU Leuven 
(P028/2011).
Metastasis assays
Intravenous injection of tumor cells has been used as 
an experimental model to investigate tumor cell metastasis 
in mice [35]. Thus, 106 (2.106 for mortality experiments) 
F2T-luc2.9 cells were injected into the tail vein of SCID 
mice. Intraperitoneal (i.p.) treatment with CDV (150 mg/
kg) was started 1 h after cell injection and continued once 
weekly. The same volume of phosphate-buffered saline 
(PBS) was given to control mice. Alternatively, F2T-
luc2.9 cells were pretreated with 10 µg/ml of CDV for 24 
h. Next, 106 cells (untreated or pretreated with CDV) were 
injected into the tail vein of SCID mice. 
B16-F10-luc2 cells were pretreated with 10 or 50 
µg/ml of CDV for 24 h. Next, 30,000 cells were injected 
into the tail vein of SCID mice.
The mice were imaged at regular time intervals to 
assess the growth of the luciferase-positive tumor cells. 
Before imaging, the mice were injected subcutaneously 
(s.c.) with 200 µl of a 15 mg/ml luciferin solution in PBS. 
Images were captured by the IVIS spectrum imaging 
system (Caliper Life Sciences, Hopkinton, MA, USA) and 
analyzed using the LivingImage software (Caliper Life 
Sc). At the end of the experiment (as indicated in Results), 
the lungs were weighed and processed for further analysis.
Clonogenic assay for viability of lung-arrested 
tumor cells
106 F2T-luc2.9 cells (treated or untreated with CDV) 
were injected i.v. in SCID mice. At different time points 
after cell injection (30 min, 24 h, 7 days) lungs were 
removed, minced and incubated in DMEM containing 
0.25% collagenase type 4 (Sigma-Aldrich) and 300 units 
DNase I for 1 h at 37°C with agitation. The cells were then 
passed through a 40 µm cell strainer to collect a single-
cell suspension. A total of 5 x 104 lung-derived cells were 
plated into a 10-cm tissue culture dish. Colonies were 
stained and counted 14 days later.
Primary tumor growth in mice
SCID mice were inoculated s.c. with 200 µl of 
serum-free DMEM containing 106 F2T.luc2.9 cells 
(untreated or pretreated with 10 µg/ml CDV) or 30,000 
B16-F10-luc2 cells (untreated or pretreated with 10 or 
50 µg/ml CDV). The mice were imaged at regular time 
intervals to assess the growth of the luciferase-positive 
tumor cells. At the end of the experiment, the tumors were 
excised and weighed. 
Histological and immunohistochemical analyses
At indicated time points, mice were euthanized by 
i.p. injection of pentobarbital. Lungs were washed with 
PBS via intracardiac perfusion and fixed intratracheally 
with 4% paraformaldehyde. Dissected lungs were 
fixed overnight at room temperature and stored in PBS 
until paraffin sectioning. Paraffin-embedded sections 
were deparaffinized in xylene and rehydrated through a 
decreasing concentration of alcohol. Four micron sections 
were prepared and subsequently stained with hematoxylin 
and eosin (H&E). The presence of metastatic nodules in 
the lungs was evaluated microscopically.
For immunohistochemistry, heat-induced antigen 
retrieval was done in citrate buffer (pH 6) using a 
microwave. Sections were permeabilized for 30 min at 
room temperature with 0.25% Triton X-100 (Sigma) in 
PBS containing 0.5% BSA, washed with PBS and blocked 
with 5% goat serum (Sigma) in PBS containing 0.5% BSA 
for 30 min at room temperature. After washing, sections 
were incubated overnight at 4°C with a rabbit anti-CD31 
(5 µg/ml, abcam), rat anti-Ki67 (1 µg/ml, eBioscience) or 
mouse anti-p53 (4 µg/ml, Novus Biologicals, Cambridge, 
UK). After washing with PBS containing 0.01% Tween20, 
sections were incubated for 3 h at room temperature with 
an Alexa Fluor 568 goat anti-rabbit antibody (Molecular 
probes), Alexa Fluor 647 goat anti-mouse antibody 
(Molecular probes) and Dylight 650 conjugated goat anti-
rat antibody (Thermofisher). Sections were washed with 
Oncotarget4645www.impactjournals.com/oncotarget
PBS containing 0.01% Tween20 and incubated with 2 µg/
ml Hoechst (Sigma) for 30 min at room temperature. After 
washing, sections were mounted with 1% n-propyl gallate 
and sealed with nail polish. Fluorescent microscopic 
analysis was done with an Axiovert 200 M inverted 
microscope (Zeiss, Göttingen, Germany), using a Plan-
Apochromat 20x/0.8 objective. Pictures were taken with 
an AxioCam MRm camera and processed with AxioVision 
Release 4.6 software (Zeiss).
Western blot analysis of lung samples
Homogenized lungs were lysed on ice in 500 µl 
lysis buffer [20 mM Tris-HCl (pH 7.4), 137 mM NaCl, 
2 mM EDTA (pH 7.4), 1% Triton X-100, 10% glycerol, 
1 mM sodium vanadate, 2 mM sodium pyrophosphate, 
1 mM phenylmethylsulfonyl fluoride, 25 mM 
glycerophosphate and 10 µg/ml leupeptin]. Lysates were 
cleared by centrifugation and the protein concentration 
was determined. SDS-PAGE gel electrophoresis of the 
cell lysates were performed as described [29]. After 
electrophoresis, proteins were transferred to pretreated 
Hybond-P polyvinylidene difluoride (PVDF) membranes 
(Amersham Biosciences). The membranes were incubated 
for 1h at room temperature in blocking buffer (5 % non-fat 
dry milk in PBS containing 0.1% Tween) and subsequently 
for 12 h at 4°C in blocking buffer with primary antibodies 
raised against β-actin (1/5000, Sigma) or FGF2 (clone FB-
8, 1/5000, Sigma). After washing, the membranes were 
incubated with the corresponding horseradish peroxidase-
conjugated secondary antibody (anti-mouse: 1/2000 or 
anti-rabbit: 1/4000, Dako) in blocking buffer for 25 min 
at room temperature. Next, the membranes were washed 
extensively. Immunoreactive proteins were detected by 
chemiluminescence (ECLplus, Bio-Rad). Samples were 
collected from 3 independent experiments. 
Metastasis assay in zebrafish embryos
The wild-type AB zebrafish line was maintained 
at the Zebrafish Facilities of the University of Brescia as 
described [69]. B16-F10 melanoma cells stably transfected 
with DsRed fluorescent protein (DsRed-B16-F10 cells) 
were injected in the blood circulation in the ventral 
region of the duct of Cuvier of zebrafish embryos (80-100 
cells/embryo) at 48 h post-fertilization (hpf). After 24 h, 
embryos were transferred in fish water in the absence or 
in the presence of 100 µg/ml of CDV and the growth of 
tail micrometastases was followed under a fluorescence 
stereo microscope and quantified 5 days after cell 
injection by computerized image analysis of the embryo 
tails as described [38]. After cell injection, embryos were 
maintained at 33°C throughout the whole experimental 
period.
Statistical analyses
Two-tailed Student’s t test was used to determine the 
statistical significance of the data; p values < 0.05 were 
considered significant.
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